Novelty treatment for Lung Cancer specifically NSCLC Takayuki, N. (2018). Advanced Non-Small-Cell Lung Cancer in Elderly Patients. Hindawi,2018, 1-8.doi: 10.1155/2018/8202971 This research discuss the study on the treatment of non-small-cell lung cancer, targeting on elderly patients. Takayuki, a biomedical researcher from Japan specialises non-small-cell lung cancer across all patients, however, in this research, his main focus is upon elders. The department of Pulmonary Medicine and the Kyoto Prefectural University of Medicine propose that chemotherapeutic treatments is unfavourable towards elderly patients due to the progressively harsh side effects. The research article therefore presents numerous novelty treatments to treat the disease in an effective manner. It has come to consideration that as people age, degeneration occurs including; the reduced ability to perform daily activities, tackling over morbid diseases over the years and the declination in organ function. Anaplastic lymphoma kinase (ALK) inhibitors are currently developed and are among the treatment options for lung cancer. Immune checkpoint inhibitors; Nivolumab presents convincing outcomes in lung cancer. As people age, their cytotoxic t cells, (which ultimately kills targeted cancer cells) heavily deteriorates. This therefore limits the duty of apoptosis to kill unwanted and damaged cells. Nivolumab is an immune checkpoint inhibitor that is actively transported into the body as a replacement of cytotoxic t cells. Although immune checkpoint inhibitors are a mandatory supplement into killing cancer cells, a limitation suggest that it should be recognised as an assistance to treating lung cancer rather than the main priority. The recognition that this immune checkpoint inhibitor is regarded as safe due it being non harmful to the body by causing abdominal illnesses such as “general condition, such as anorexia, malaise, and myelosuppression” that develop poor health. In closing, Takayuki presented useful novel treatments of cancer for elderly patients, however the lack of results shown limits the evidence that there is effectiveness of the therapeutic treatments. The article touched basis on the constraints and consideration to their target audiences by the production of the inhibitors which are useful to tackling cancer. Md Maksudul, A., Sagar, S., Massoud G., Zhang L., Li, Z., Sarada Preeta, K. (2016). Cyclopamine Tartrate, an inhibitor of Hedgehog signaling, strongly interferes with Mitochondrial function and suppresses aerobic respiration in lung cancer cells. BMC Cancer. 1-10.doi: 10.1186/s12885-016-2200-x This research article explores how hedgehog signaling specifically cyclopamine tartrate is linked with the eradication of cancers including lung cancer. Researchers including Maksudul, from the University of Texas under the department of Biochemistry and Molecular of Biology have conducted that cyclopamine tartrate, an inhibitor is an effective strategy into conquering cancer cells. Cyclopamine tartrate ‘s function is signaling pathways has been an intensely investigated area for cancer lung therapy, and signaling are being tested clinically for treating many cancers. The novel strategies for eliminating lung cancer, researchers proposed to characterize the effect of cyclopamine tartrate on lung cancer cells and its mechanism of action. To conclude it is demonstrated that Cyclopamine tartrate can interrupt non-small-cell lung cancer cell function by promoting mitochondrial, overall destroying mitochondrial respiration and vanquishing cell growth, causing apoptosis. Although cyclopamine tartrate may be a novelty treatment against cancer cells, it is mentioned that it is not resistant when it comes to its poor solubility, and acidic sensitivity. This article demonstrated useful information towards how the inhibitors work therefore developing an understanding on the disease as well as the treatment. Casadei, A., Chiadini, E., Faloppi, L., Marisi, G., Delmonte, A., Scartozzi, M., Loretelli, C., Lucchesi, A., Oboldi, D. , Dubini, A., Frassineti. G, Ulivi, P. (2016). Efficacy of sorafenib in BRAF-mutated non- small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type- hepatocellular carcinoma. BMC Cancer,16, 1-5.doi:10.1186/s12885-016-2463-2 This research highlights how Sorafenib, a kinase inhibitor eliminates cancer cells within the lungs. A case study was conducted on a 74 year old smoker with non-small-cell lung was experimented by the Sorafenib inhibitor. The patient was given 400mg of Sorafenib for a certain amount of time until proper progression occurs. It was shown that the primary lung lesion was measured to be 40.9 mm × 29.3 mm. The diagram demonstrates three seperate images of the lung which are six months between each other. The second diagram demonstrates the significant decrease of the lung lesion which estimates a 27 mm × 25 mm. However, the last image which represents one year after the treatment highlighting the regrowth of the cancer in the lung. This analyses that this treatment may be beneficial yet not intended to be curable. This text presented many graphical statistics overtime which were beneficial on viewing the overall results of the sorafenib inhibitor. In conclusion, our results suggest that sorafenib inhibitor could be useful in BRAF-mutated tumors, which are tumors that are relatively small. It would be beneficial that in the future, it would be worth trying this treatment upon small cancer cells.